Joshua Jennings
Stock Analyst at TD Cowen
(3.30)
# 987
Out of 5,182 analysts
82
Total ratings
47.44%
Success rate
4.03%
Average return
Main Sectors:
Stocks Rated by Joshua Jennings
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| HUMA Humacyte | Maintains: Buy | $3.5 → $1 | $0.81 | +24.08% | 4 | Mar 30, 2026 | |
| BFLY Butterfly Network | Maintains: Buy | $4.5 → $6 | $5.48 | +9.49% | 1 | Feb 27, 2026 | |
| PRCT PROCEPT BioRobotics | Maintains: Buy | $50 → $34 | $24.09 | +41.14% | 5 | Feb 26, 2026 | |
| BSX Boston Scientific | Maintains: Buy | $115 → $100 | $59.95 | +66.81% | 8 | Feb 5, 2026 | |
| JNJ Johnson & Johnson | Maintains: Buy | $222 → $250 | $225.34 | +10.94% | 2 | Jan 22, 2026 | |
| EW Edwards Lifesciences | Upgrades: Buy | $90 → $97 | $83.46 | +16.22% | 2 | Jan 9, 2026 | |
| OBIO Orchestra BioMed Holdings | Initiates: Buy | $15 | $4.10 | +265.85% | 1 | Dec 10, 2025 | |
| CBLL CeriBell | Maintains: Buy | $36 → $20 | $21.14 | -5.39% | 3 | Nov 5, 2025 | |
| SENS Senseonics Holdings | Maintains: Buy | $25 → $15 | $7.27 | +106.33% | 2 | Nov 5, 2025 | |
| DXCM DexCom | Maintains: Buy | $100 → $84 | $61.41 | +36.79% | 2 | Oct 31, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $15 | $5.66 | +165.02% | 1 | Jan 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $264 → $324 | $188.31 | +72.06% | 1 | Jan 3, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $175 → $120 | $108.12 | +10.99% | 9 | Nov 18, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Hold | $143 → $119 | $92.59 | +28.52% | 1 | Sep 6, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $55 → $60 | $36.98 | +62.25% | 2 | Aug 27, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Hold | $83 → $80 | $74.13 | +7.92% | 1 | Aug 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $135 → $45 | $4.40 | +923.89% | 3 | Aug 8, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Hold | $40 | $18.49 | +116.33% | 4 | May 10, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $365 → $400 | $329.01 | +21.58% | 2 | Apr 11, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $50 → $60 | $65.47 | -8.35% | 4 | Mar 12, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $52 → $34 | $19.82 | +71.54% | 2 | Aug 4, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $14 → $18 | $6.79 | +165.19% | 3 | May 11, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $6 → $25 | $16.57 | +50.88% | 1 | Dec 30, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $130 | $92.80 | +40.09% | 9 | Dec 13, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $7 → $5 | $1.93 | +159.07% | 1 | Nov 11, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $125 → $117 | $82.92 | +41.10% | 3 | May 27, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $12 | $10.36 | +15.83% | 1 | Sep 3, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | $306 → $275 | $150.22 | +83.06% | 1 | Feb 7, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | $28 → $28 | $9.94 | +176.66% | 3 | Sep 5, 2018 |
Humacyte
Mar 30, 2026
Maintains: Buy
Price Target: $3.5 → $1
Current: $0.81
Upside: +24.08%
Butterfly Network
Feb 27, 2026
Maintains: Buy
Price Target: $4.5 → $6
Current: $5.48
Upside: +9.49%
PROCEPT BioRobotics
Feb 26, 2026
Maintains: Buy
Price Target: $50 → $34
Current: $24.09
Upside: +41.14%
Boston Scientific
Feb 5, 2026
Maintains: Buy
Price Target: $115 → $100
Current: $59.95
Upside: +66.81%
Johnson & Johnson
Jan 22, 2026
Maintains: Buy
Price Target: $222 → $250
Current: $225.34
Upside: +10.94%
Edwards Lifesciences
Jan 9, 2026
Upgrades: Buy
Price Target: $90 → $97
Current: $83.46
Upside: +16.22%
Orchestra BioMed Holdings
Dec 10, 2025
Initiates: Buy
Price Target: $15
Current: $4.10
Upside: +265.85%
CeriBell
Nov 5, 2025
Maintains: Buy
Price Target: $36 → $20
Current: $21.14
Upside: -5.39%
Senseonics Holdings
Nov 5, 2025
Maintains: Buy
Price Target: $25 → $15
Current: $7.27
Upside: +106.33%
DexCom
Oct 31, 2025
Maintains: Buy
Price Target: $100 → $84
Current: $61.41
Upside: +36.79%
Jan 7, 2025
Initiates: Buy
Price Target: $15
Current: $5.66
Upside: +165.02%
Jan 3, 2025
Maintains: Buy
Price Target: $264 → $324
Current: $188.31
Upside: +72.06%
Nov 18, 2024
Maintains: Buy
Price Target: $175 → $120
Current: $108.12
Upside: +10.99%
Sep 6, 2024
Maintains: Hold
Price Target: $143 → $119
Current: $92.59
Upside: +28.52%
Aug 27, 2024
Maintains: Buy
Price Target: $55 → $60
Current: $36.98
Upside: +62.25%
Aug 13, 2024
Maintains: Hold
Price Target: $83 → $80
Current: $74.13
Upside: +7.92%
Aug 8, 2024
Maintains: Buy
Price Target: $135 → $45
Current: $4.40
Upside: +923.89%
May 10, 2024
Downgrades: Hold
Price Target: $40
Current: $18.49
Upside: +116.33%
Apr 11, 2024
Maintains: Buy
Price Target: $365 → $400
Current: $329.01
Upside: +21.58%
Mar 12, 2024
Maintains: Outperform
Price Target: $50 → $60
Current: $65.47
Upside: -8.35%
Aug 4, 2023
Maintains: Outperform
Price Target: $52 → $34
Current: $19.82
Upside: +71.54%
May 11, 2023
Maintains: Outperform
Price Target: $14 → $18
Current: $6.79
Upside: +165.19%
Dec 30, 2022
Maintains: Outperform
Price Target: $6 → $25
Current: $16.57
Upside: +50.88%
Dec 13, 2022
Maintains: Outperform
Price Target: $130
Current: $92.80
Upside: +40.09%
Nov 11, 2022
Maintains: Outperform
Price Target: $7 → $5
Current: $1.93
Upside: +159.07%
May 27, 2022
Maintains: Outperform
Price Target: $125 → $117
Current: $82.92
Upside: +41.10%
Sep 3, 2020
Initiates: Outperform
Price Target: $12
Current: $10.36
Upside: +15.83%
Feb 7, 2020
Downgrades: Market Perform
Price Target: $306 → $275
Current: $150.22
Upside: +83.06%
Sep 5, 2018
Downgrades: Market Perform
Price Target: $28 → $28
Current: $9.94
Upside: +176.66%